Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eclitasertib SCHEMBL19207477 | 1.00 | RIPK1 (0.77) | RIPK1NR1I2CYP2C9 | |
| Eclitasertib SCHEMBL19224719 | 1.00 | RIPK1 (0.77) | RIPK1NR1I2CYP2C9 | |
| Eclitasertib SCHEMBL19207584 | 0.94 | RIPK1 (0.69) | RIPK1NR1I2CYP2C9 | |
| Eclitasertib SCHEMBL19207582 | 0.94 | RIPK1 (0.69) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL22736926 | 0.92 | RIPK1 (0.66) | RIPK1 | |
| SCHEMBL22737137 | 0.92 | RIPK1 (0.66) | RIPK1 | |
| SCHEMBL19207613 | 0.88 | RIPK1 (0.76) | RIPK1 | |
| SCHEMBL29415769 | 0.88 | RIPK1 (0.76) | RIPK1 | |
| SCHEMBL19207609 | 0.88 | RIPK1 (0.76) | RIPK1 | |
| SCHEMBL19224733 | 0.88 | RIPK1 (0.65) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999750-B2 | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide | DENALI THERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20230271978-A1 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | DENALI THERAPEUTICS INC. | 2023-08-31 | — | — | US | claimed |
| WO-2023137035-A1 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2, 3,4,5- TETRAHYDROPYRIDO [3,2-B] [L,4]OXAZEPIN-3-YL)-4H-L,2,4-TRIAZOLE-3-CARBOXAMIDE | DENALI THERAPEUTICS INC. (US) | 2023-07-20 | — | — | WO | claimed |
| EP-4135705-A1 | ECLITASERTIB FOR USE IN TREATING CONDITIONS INVOLVING SYSTEMIC HYPERINFLAMMATORY RESPONSE | GENZYME CORPORATION (US) | 2023-02-22 | — | — | EP | claimed |
| WO-2021211919-A1 | ECLITASERTIB FOR USE IN TREATING CONDITIONS INVOLVING SYSTEMIC HYPERINFLAMMATORY RESPONSE | GENZYME CORPORATION (US) | 2021-10-21 | — | — | WO | claimed |
| US-12043629-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11999750-B2 | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide | DENALI THERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11999750-B2 | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide | DENALI THERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20230271978-A1 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | DENALI THERAPEUTICS INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230271978-A1 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | DENALI THERAPEUTICS INC. | 2023-08-31 | — | — | US | disclosed |
| WO-2023137035-A1 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2, 3,4,5- TETRAHYDROPYRIDO [3,2-B] [L,4]OXAZEPIN-3-YL)-4H-L,2,4-TRIAZOLE-3-CARBOXAMIDE | DENALI THERAPEUTICS INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| CN-115867548-A | RIP1K inhibitors | 里格尔药品股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11584758-B2 | RIP1K inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4126864-A1 | RIP1K INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20210317135-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2021203011-A1 | RIP1K INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| EP-3414239-A2 | INHIBITORS OF RECEPTOR-INTERACTING PROTEIN KINASE 1 | Denali Therapeutics Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-9896458-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584758-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885NR1I2 1753/4885CYP2C9 4864/4885 |
| US-11999750-B2 | Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide | CYP4B1, CYP3A4, HTR3C | RIPK1 3343/4885NR1I2 233/4885CYP2C9 84/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885NR1I2 4071/4885CYP2C9 3496/4885 |
| US-12043629-B2 | RIP1K inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885NR1I2 1753/4885CYP2C9 4864/4885 |
| US-20210317135-A1 | RIP1K INHIBITORS | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885NR1I2 1753/4885CYP2C9 4864/4885 |
| US-20230271978-A1 | CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE | CYP4B1, CYP3A4, HTR3C | RIPK1 3343/4885NR1I2 233/4885CYP2C9 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.